Management of Crohn’s disease in adults

American Journal of Gastroenterology

Volumn 96, Issue 3, 2001, Pages 635-643

  Hanauer, Stephen B ^a,b   Sandborn, William ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; STEROID;

ABDOMINAL PAIN; CONTRAST RADIOGRAPHY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; ENDOSCOPY; FEVER; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REVIEW; WEIGHT REDUCTION;

ADULT; CROHN DISEASE; HUMANS;

EID: 0035074301     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02234-1     Document Type: Review

References (128)

1. Inflammatory bowel disease: Etiology and pathogenesis
2. Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival
3. Inflammatory bowel disease incidence: Up, down or unchanged?
4. Review articles: Drug therapy, inflammatory bowel disease
5. Low symptomatic load in Crohn's disease with surgery and medicine as complementary treatments
6. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort
7. Clinical economics review: Medical management of inflammatory bowel disease
8. Advances in the management of Crohn's disease: Economic and clinical potential of infliximab
9. Management of Crohn's disease in adults
10. Therapeutics and inflammatory bowel disease: A guide to the interpretation of randomized controlled trials
11. Inflammatory bowel diseases with onset in childhood: Clinical features, morbidity, and mortality in a regional cohort
12. Differences in the management of inflammatory bowel disease in children and adolescents compared to adults
13. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease: Results of a large, prospective population-based study in southeastern Norway, 1990-93
14. Long-term follow-up of patients with Crohn's disease: Relationship between the clinical pattern and prognosis
15. Proposed classification of patient subgroups in Crohn's disease
16. Clinical features and natural history of Crohn's disease
17. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1996 A 36-year-old man with right-lower-quadrant pain of two years' duration
18. Anal pathology in patients with Crohn's disease
19. Clinical course of colorectal Crohn's disease: A 35-year follow-up study of 507 patients
20. Differentiation between Crohn's disease and ulcerative colitis
21. Diffuse jejuno-ileitis of Crohn's disease: A separate form of the disease?
22. Clinical aspects of Crohn's disease of the upper gastrointestinal tract: A comparison with distal Crohn's disease
23. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease
24. Risk factors and distinguishing features of cancer in IBD
25. A prospective study of first attacks of inflammatory bowel disease and infectious colitis: Clinical findings and early diagnosis
26. Factors influencing the relapse of patients with inflammatory bowel disease
27. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease
28. Antibody 'markers' in Crohn's disease: Opportunity or overstatement?
29. Lack of current clinical value of serological testing in the evaluation of patients with IBD
30. A prospective randomized comparison between small bowel enteroclysis and small bowel follow-through in Crohn's disease
31. Radiologic evaluation of Crohn disease
32. Imaging modalities in inflammatory bowel disease
33. Crohn's disease: New imaging techniques
34. The role of colonoscopy in the management of patients with inflammatory bowel disease
35. Clinical, biological, and endoscopic picture of attacks of Crohn's disease: Evolution on prednisolone
36. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
37. Crohn's disease of the upper gastrointestinal tract: The value of endoscopic examination
38. High incidence of upper gastrointestinal tract involvement in Crohn's disease
39. Predictability of the postoperative course of Crohn's disease
40. Inflammatory bowel disease and smoking - A review
41. Psychosocial factors in inflammatory bowel disease
42. Practice guidelines for inflammatory bowel disease: An instrument for assessment
43. Standards for approval of new drugs for IBD
44. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study
45. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index
46. Quality of life issues in patients with inflammatory bowel disease
47. Narcotic dependence in inflammatory bowel disease
48. National Cooperative Crohn's Disease Study: Results of drug treatment
49. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
50. The clinical effect of Salazosulphapyridine (Salazopyrin) in Crohn's disease: A controlled double-blind study
51. Effect of sulphasalazine in patients with active Crohn's disease: A controlled double-blind study
52. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease
53. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
54. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis
55. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial
56. Second trial of mesalamine therapy in the treatment of active Crohn's disease
57. Double blind, placebo controlled trial of metronidazole in Crohn's disease
58. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. II. Result
59. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease
60. Combination ciprofloxacin and metronidazole for active Crohn's disease
61. Use of antibiotics in the treatment of active Crohn's disease: Experience with metronidazole and ciprofloxacin
62. Anti-tuberculous therapy for maintaining remission of Crohn's disease
63. Clinical effectiveness of various budesonide preparations in Crohn disease
64. Omeprazole for duodenal ulceration in Crohn's disease
65. Omeprazole for peptic ulcer in Crohn's disease
66. Omeprazole in possible esophageal Crohn's disease
67. Is omeprazole helpful in inflammatory bowel disease
68. Diffuse jejunoileitis of Crohn's disease
69. Corticosteroid treatment in active Crohn's disease
70. A comparison of budesonide with prednisolone for active Crohn's disease
71. Oral budesonide is as effective as oral prednisolone in active Crohn's disease
72. Budesonide versus prednisone in the treatment of active Crohn's disease
73. Oral budesonide for active Crohn's disease
74. Frequency of glucocorticoid resistance and dependency in Crohn's disease
75. Clinical pattern of corticosteroid dependent Crohn's disease
76. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn's disease
77. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance
78. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
79. Azathioprine: State of the art in inflammatory bowel disease
80. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease
81. Methotrexate for the treatment of Crohn's disease
82. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
83. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
84. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
85. Critical appraisal of enteral nutrition as primary therapy in adults with Crohn's disease
86. Nutrition and inflammatory bowel disease
87. The safety of corticosteroid therapy in Crohn's disease with an abdominal mass
88. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials
89. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: A randomized double-blind study and follow-up
90. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine
91. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease
92. Steroid-unresponsive acute attacks of inflammatory bowel disease: Immunomodulation by tacrolimus (FK506)
93. Cyclosporin for severe ulcerative colitis: A user's guide
94. Healing of perineal Crohn's disease with metronidazole
95. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease
96. Metronidazole therapy for perineal Crohn's disease: A follow-up study
97. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A
98. Efficacy of cyclosporine in treatment of fistula of Crohn's disease
99. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease
100. Treatment of Crohn's disease with 6-mercaptopurine: A long-term, randomized, double-blind study
101. Infliximab for the treatment of fistulas in patients with Crohn's disease
102. Corticosteroids for maintaining remission of Crohn's disease
103. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study
104. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease
105. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo- controlled trial
106. Oral budesonide as maintenance therapy in Crohn's disease-Results of a 12-month study
107. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease
108. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
109. Azathioprine for maintenance of remission of Crohn's disease
110. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
111. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience
112. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity
113. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease
114. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
115. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease
116. Review article: The risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease
117. Methotrexate for inflammatory bowel disease: Pharmacology and preliminary results
118. Low-dose cyclosporine for the treatment of Crohn's disease
119. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study
120. Preventing postoperative recurrence of Crohn's disease
121. Adjuvant post-operative therapy
122. Postoperative recurrence of Crohn's disease in relation to radicality of Operation and sulfasalazine prophylaxis: A multicenter trial
123. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection
124. Prognostic parameters of Crohn's disease recurrence
125. Surgical therapy for ulcerative colitis and Crohn's disease
126. Evolution of surgery for Crohn's disease: A century of progress
127. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: A prospective study
128. Impact of surgery on quality of life in Crohn's disease